

fusion protein, a sodium channel antagonist, an NMDA antagonist, and a 5HT1 agonist.

Remarks

Currently Claims 5-6, 14-15, and 19-29 are pending. Claims 1-4, 7-13, and 16-18 are canceled. Claims 5-6 and 14-15 have been amended to conform the claims to standard US practice. Claims 19-29 have been added to complete the record. Support for these claims can be found in Applicants' original specification, particularly at original claims 1-18. No new matter is added.

An abstract on a separate page is provided herewith.

Applicants respectfully submit that the instant application is in condition for substantive examination, which action is respectfully requested. The Examiner is invited to contact the undersigned at 483-8222, to discuss this case further if desired.

Respectfully submitted,



Lorie Ann Morgan

Attorney for Applicants  
Registration No. 38,181

Date: 5 Feb. 02  
Glaxo Wellcome Inc.  
Five Moore Drive, PO Box 13398  
Research Triangle Park  
North Carolina 27709  
(919) 483-8222

Abstract

The present invention relates to the use of an EP4 receptor ligand in the manufacture of a medicament for use in the treatment of neuropathic pain, colon cancer, migraine, and for increasing the latency of HIV infection.

205020" 24 FEB 00

## Marked-up Claims

5. (Amended) A method of treating neuropathic pain in a mammal[, including man,] comprising [administration of] administering an effective amount of an EP4 receptor ligand.
6. (Amended) A method of treating colon cancer in a mammal[, including man,] comprising [administration of] administering an effective amount of an EP4 receptor ligand.
14. (Amended) A method of treating neuropathic pain in a mammal[, including man,] comprising [administration of] administering an effective amount of an EP4 receptor antagonist.
15. (Amended) A method of treating colon cancer in a mammal[, including man,] comprising [administration of] administering an effective amount of an EP4 receptor antagonist.